Sanofi
Q2 2023 Earnings Call
Jul 28, 2023, 8:30 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Eva Schaefer-Jansen
Good morning, good afternoon, and good evening to everyone. Thank you for joining us to review Sanofi's second quarter 2023 results, followed by a Q&A session. As usual, you can find the slides to this call on the investors page on our website at sanofi.com. Moving to Slide 3, I would like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially.
I refer you to our Form 20-F document on file with the SEC, and also our Document d'Enregistrement Universel for a description of these risk factors. With that, please advance to Slide 4. Our speakers on the call today are Paul Hudson, chief executive officer; Dietmar Berger, global head of R&D at interim; the global business unit heads, Bill Sibold, Thomas Triomphe, Olivier Charmeil and Julian van Ongevalle; and Jean-Baptiste de Chatillon, the chief financial officer. [Operator instructions] And with that, I'd like to turn the call over to Paul.
Paul Hudson -- Chief Executive Officer
Well, thank you, Eva, and thanks to everyone for joining our call today. Together with members of the executive team, I'll take you through Sanofi's business and financial performance in the second quarter of 2023. Starting with our sales performance on Slide 6, we delivered another quarter of growth in Q2 with Specialty Care and Vaccine as the key drivers. In Specialty Care, sales were up double-digit in the quarter, driven mainly by Dupixent which continues its outstanding growth trajectory.
Vaccine sales were up by more than 9%, and we shared with you our excitement for this growing business at our Vaccine investor event last month in London. The approval of Beyfortus in the US earlier in July and the ACIP meeting taking place next week give us strong confidence to continue to deliver mid-to-high single-digit sales growth in vaccines as previously guided. Core assets in General Medicines and Consumer Healthcare also continued to grow. Aubagio, our last meaningful LOE in the decade, as well as non-core assets in GenMed declined as anticipated.
In summary, based on solid performance and expected healthy underlying momentum in the second half of 2023, we upgrade our financial guidance for the full year. On the next slide, well, let's have a look at the sales performance in the first half as it looks beyond some impacts from quarterly phasing. Combined, our key growth drivers were up more than 15%, which we believe is a great emerging proof point of our successful portfolio transformation toward innovative medicines. Of note, our stand-alone Consumer Healthcare business grew 6% in the first half, while we continue to streamline the CHC product portfolio and divest smaller non-strategic brands.